Breaking
new ground

in immuno-oncology

Breaking
new ground

in immuno-oncology

Immunocore

Breaking new ground in immunotherapy

Immunocore is the world’s leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform. The scientific expertise at Immunocore spans the entire process of drug development. From the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, and preclinical and clinical assessment.

panel-1.jpg

Discovery and
validation of novel
disease targets
 

Learn more

 

panel-2.jpg

ImmTAC – redefining
immuno-oncology
through TCR targeted
T cell redirection

Learn more

 

panel-3.jpg

ImmTAC molecules in the
clinic – delivering
better tomorrows
 

Learn more